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Abstract 
 Experience sampling methodology (ESM) involves completing questionnaires during 
daily life and has been used extensively in people with schizophrenia to assess symptoms 
and behaviours. Despite considerable advantages over interview measures, there is limited 
information about its external validity. Our aim is to investigate whether ESM protocol 
implementation is affected differentially in people with schizophrenia and healthy 
individuals by factors such as mood, medication and symptoms which would have 
implications for validity. Fifty-three people with schizophrenia and fifty-eight controls from 
the general population completed seven ESM questionnaires per day for six consecutive 
days. Compliance and acceptability, including overall experience, training and disruption of 
normal routines, were recorded.  Overall questionnaire completion rate in people with 
schizophrenia was comparable to controls (i.e. over 70%). People with schizophrenia 
completed significantly fewer questionnaires in the morning but did not show fatigue 
effects over the experience sampling period. Excluding questionnaires in the morning did 
not significantly alter the findings. In the schizophrenia group medication level and 
symptoms did not influence adherence. However, higher disruption was associated with 
reduced questionnaire completion in this group. These findings suggest that minimising 
disruption may enhance validity and completion rates. ESM is a valid methodology to use 
with people with schizophrenia. 
 
Highlights  
 This is the first study to examine the validity of an ESM protocol.  
 People with schizophrenia show similar protocol compliance to healthy controls.  
 People with schizophrenia complete fewer questionnaires in the morning. 
 Medication and symptom levels do not influence questionnaire completion rates.  
 Levels of reported disruption were associated with reduced questionnaire 
completion.  
 
 
 
 
 
 
1. Introduction 
 Experience sampling methodology (ESM) is an assessment method developed to 
overcome the limitations of experimental and retrospective measures. Participants complete 
repeated assessments over several days, in response to randomly timed prompts (Kimhy, 
Myin-Germeys, Palmier-Claus, & Swendsen, 2012). ESM has many features which recommend 
it for use in studies examining mental health problems. Assessments are completed “in the 
moment” so do not rely on retrospective memory and are collected as part of a participant’s 
everyday life. ESM questionnaires assess behaviours, emotions and thoughts over time - 
providing valuable insight into the dynamics of symptom experiences in everyday life. This 
enables the identification of modifiable treatment targets with high relevance to everyday 
life. The large number of data points collected per individual compared to a single 
questionnaire also maximises the robustness of the findings and minimises the influence of 
extreme responses in statistical analyses.  
Although ESM has many advantages there are concerns about its potential burden on 
participants (Kimhy et al., 2012). There are a small number of studies that report feasibility 
data for people with schizophrenia. Studies assessing positive symptoms find over 80% 
completion rates of six questionnaires per day for a week (Kimhy, Vakhrusheva, Liu, & Wang, 
2014; Palmier-Claus et al., 2012). A review of ESM in studies including people with severe 
mental disorders reported similar compliance rates ranging from 72-81% (Kimhy et al., 2012). 
These studies also report a minimum threshold of questionnaires to be completed for 
inclusion in the study (set at 20 or 33%), the number of excluded participants ranged from 1-
9 (Oorschot et al., 2013). This study extends these current findings by examining compliance 
rates across time in both people with schizophrenia and controls as differential rates of 
responding may introduce bias. Furthermore, although missing questionnaires are reported 
in every ESM study, the impact of this missing data on the conclusions drawn has not yet been 
examined. This study investigates the effect of missing questionnaires on mood ratings and 
considers the implications for future ESM protocols.  
This study contributes to the literature by examining several factors which may 
influence this compliance and therefore reduce the validity of ESM studies. For example, 
assessments conducted over several days may be affected by fatigue and/or adherence may 
fluctuate resulting in systematic patterns of missing data. Studies have shown that 
antipsychotic medication affects the sleep-wake cycle of people with schizophrenia and 
therefore may impact adherence rates (P. Afonso, Brissos, Canas, Bobes, & Bernardo-
Fernandez, 2014; Pedro Afonso, Figueira, & Paiva, 2014). In addition mood or low motivation 
may be implicated in diurnal variation in completion rates. This could reduce the 
representativeness of the assessments, especially in comparison to healthy controls. Factors 
such as medication dosage and symptom levels may also act as moderators of protocol 
compliance i.e. medication may moderate the relationship between symptom levels and 
questionnaire completion rates. These more complex relationships are yet to be investigated 
in the literature.  
Despite the high potential utility of ESM protocols, investigations of the validity of 
these data are lacking. In particular, one controversial issue that ESM research has not dealt 
with is responsivity. This refers to participants changing their typical behaviours to be more 
available for the questionnaires or in response to some of the questions asked. This can limit 
the ecological validity of the findings and this study aimed to address this to increase 
confidence in the conclusions drawn from this methodology. Furthermore, two previous 
studies have reported the experience of the participants in these studies as acceptable, 
although both only included a sample size of 10 (Depp et al., 2010; Kimhy et al., 2006). This 
has yet to be examined in a larger sample of people with schizophrenia and controls and 
replicating this finding was a further aim of this study.  
The current study therefore aimed to thoroughly assess the feasibility and internal 
validity of ESM studies for the first time by addressing the following research questions:  
 Are there different compliance rates over time in people with schizophrenia 
compared to controls?  
 Do participants indicate significant changes to their usual routines as a result 
of completing the ESM study which may indicate responsivity? 
 Do participants find the experience of taking part in an ESM study acceptable? 
 Do medication, symptoms or levels of disruption influence compliance and 
therefore potentially confound the results? Are there important moderating 
relationships between these variables?  
 Do missing questionnaires significantly alter the overall ratings of mood? 
2. Method 
2.1 Sample 
Participants with diagnoses of schizophrenia were outpatients recruited from community 
mental health teams in South London using the following inclusion criteria: (i) DSM-IV 
diagnosis of schizophrenia or schizoaffective disorder, (ii) aged 18-65yrs, (iii) good command 
of the English language. They were excluded if they had: (i) primary DSM-IV diagnosis of 
substance abuse, (ii) severe learning difficulties (iii) changes to medication in the last 6 weeks.  
Control participants were recruited from the general population using online advertisements, 
community links Inclusion criteria: (i) no current or history of mental health problems 
according to the MINI (see below) (ii) aged 18-65yrs (iii) good command of English.  
2.2 Measures 
2.2.1 Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) was used 
to screen for current and past mental health problems in the control group. 
2.2.2 ESM questionnaires were designed to assess experiences of pleasure, motivation and 
socialising in everyday life. Positive and negative affect were measured alongside these 
variables as a potential moderator of symptoms in schizophrenia (Oorschot, Lataster, 
Thewissen, Lardinois, et al., 2012; Oorschot, Lataster, Thewissen, Wichers, & Myin-Germeys, 
2012; Thewissen et al., 2011). Participants were asked to respond to all ESM questions using 
either Likert scales (1-7) or category boxes e.g. “Right now I feel anxious” 1 (not at all)-7 (very 
much so). The questionnaires, methodology and device were reviewed and received approval 
from a service user advisory group within the Service User Research Enterprise (Rose & 
Wykes, 2001).  
2.2.3 Experience Feedback Questionnaire (EFQ) was developed using participatory 
methodology (Evans et al., 2012) with contributions from service users. It was then reviewed 
and approved by a service user advisory group to ensure it covered relevant concerns. The 
questionnaire identified issues that might affect disruption (ease of use, enjoyment, 
embarrassment etc.) as well as directly asking about disruption to typical routines or 
activities. Items were rated on a 7-point Likert Scale and averaged to provide an acceptability 
score for the overall experience and disruption. A score of 4-7 (from 1-7) was considered 
acceptable.  
2.2.4 Potential Moderators of Protocol Compliance 
Symptom severity in the schizophrenia group was assessed with the Positive and Negative 
Syndrome Scale (PANSS) (Kay, Opler, & Lindenmayer, 1988). We derived five symptom 
domains according to (Wallwork, Fortgang, Hashimoto, Weinberger, & Dickinson, 2012) as 
this produces separate scales for disorganisation and negative symptoms which may have 
distinct effects on compliance (Cella, Reeder, & Wykes, 2014). All participants completed a 
demographic questionnaire which collected information regarding age, gender, ethnicity and 
medication, dosages were checked on electronic medical records and chlorpromazine 
equivalent dosages were calculated (Woods, 2003).  
2.3 Procedure 
The experience sampling questionnaire was administered using  a small portable device called 
a PsyMate (Maastricht University) with a touch-screen that displays questionnaires and 
records answers. At the initial session participants were shown how to use the PsyMate and 
completed a practice assessment as well as the PANSS and demographic questionnaire. The 
PsyMate was used for the next 6 days and was programmed to beep 7 pseudo-random times 
a day between 8.30am and 10pm with at least 45mins between beeps. A 20 minute window 
was allowed to complete the questionnaire after the prompt. If the questionnaire was not 
completed within this time it was recorded as “missed”.  
During the ESM assessment week the researcher contacted the participant (generally on the 
2nd day) to check if there had been any problems. After six days the participant returned for 
a debrief session and completed the Experience Feedback Questionnaire and were 
reimbursed for their time. All participants provided written informed consent and approval 
was received from a Research Ethics Committee (12/LO/1524 and 13/LO/1791).  
2.4 Analyses  
2.4.1 Completion rates: The median and interquartile range of the overall completion rate (% 
questionnaires completed) was reported to describe the data variance. A minimum threshold 
of 20% of overall questionnaires completed was set to ensure adequate external validity of 
the ratings (Oorschot et al., 2013). The average percentage of questionnaires completed for 
each beep (1-7) and day (1-6) is reported separately and was used to index fatigue. The 
average percentage of questionnaires completed at each beep and day were compared 
within-groups using paired t-tests to ascertain significant reduction in either group. Those 
identified as significantly reduced within each group were compared between groups using a 
one-way Analysis of Variance (ANOVA) to establish whether compliance rates are significantly 
altered in one group which may limit the validity of between-group comparisons in the 
findings from the questionnaire.  
2.4.2 Feedback on the Experience of Participation: The ratings of disruption (responsivity), 
the training provided and the experience of taking part were reported for both groups.  
2.4.3 Potential Moderators of Compliance (symptoms, mood, medication and disruption): 
Effects of medication, symptom severity and disruption was tested on overall completion 
rates and on days or beeps identified as significantly lower using Pearson’s correlation 
analyses and Spearman’s Rank correlations for any non-parametric data. Correlations which 
are moderate (r=0.4) or higher were considered indicative of reduced validity of the data due 
to a disruptive influence of this factor. A power calculation determined that 46 people in each 
group were sufficient to detect a correlation of this size. Disruption, symptoms and 
chlorpromazine equivalents effects on low and high adherence were also tested using one-
way ANOVAs.  
2.4.4 Effects of compliance on ESM measures Mean values of positive and negative affect 
were calculated as these ratings provided the largest pool of data. These calculations were 
repeated after bootstrapping the data using the bootstrap Stata command (StataCorp, 2009) 
to randomly select 5 questionnaires per day. The calculations were also repeated after 
specifically excluding those time-points with the lowest completion rates. Both of these 
decisions were data-driven according to the pattern of responding identified in the 
schizophrenia group. This analysis identified any significant alterations to these values as a 
result of this missing data. The times with lower completion rates were compared to those 
which were not reduced using a paired t-test analysis.    
3. Results 
Fifty-four people with a diagnosis of a schizophrenia spectrum disorder and 58 healthy 
controls took part in the study. Only 5 (9%) people with schizophrenia and 1 (2%) control 
completed fewer than 20% of questionnaires and were therefore excluded. Table 1 presents 
the demographic characteristics of the two final groups. There were no significant differences 
between the people who were excluded and those included in the analyses on age, 
medication or symptoms except lower PANSS depression in those excluded (p<0.05).  
---------------------------------------------------Table 1 about here---------------------------------------------- 
3.1 Questionnaire Completion  
There was no difference between groups in the overall completion rate (F(1,105)=1.80, 
p=0.18). Participants with a diagnosis of schizophrenia completed, on average, 71% 
(IQR=29.5, min: 32, max: 100) of questionnaires compared to 79% (IQR=26, min: 21, max: 
100) in the control group.  
A within-group analysis revealed that people with schizophrenia respond significantly more 
often to beeps 3, 5 and 6 compared in pair-wise analyses to beeps 1, 2, 4 and 7 (p<0.05) (see 
Figure 1). However, the completion rates for these beeps were not significantly lower 
compared to the control group, with the exception of beep 7 (F(1,105)=4.50, p=0.04).  
--------------------------------------------Figure 1 about here--------------------------------------------------- 
Fatigue effects were identified by examining response rates at different days of the 
week using within-group analyses (See Figure 2). We expected poorer responding at the end 
of the week if fatigue is present but response rates did not vary considerably in either group, 
although controls did complete significantly fewer questionnaires on day 3 compared to day 
2. 
-------------------------------------------Figure 2 about here----------------------------------------------------- 
3.2 Experience Ratings  
The average ratings for each section of the questionnaire are reported in Table 1, some items 
were reversed so a higher score always reflects a better rating. In the schizophrenia group all 
of the participants found taking part in the assessment acceptable while 98% of control 
participants rated this experience as such. Disruption to the individual’s typical week was 
rated as minimal by 94% of people with schizophrenia and 100% of the control participants. 
The people in the schizophrenia group who reported high disruption (n=3) did not complete 
fewer questionnaires at Beeps, 1, 2 or 7 (F(1,48)=0.17, 0.27, 1.69 respectively, p>0.05) than 
those who rated disruption as minimal (n=46). However, there was a significant, moderate 
association between disruption ratings and questionnaire completion rates in the 
schizophrenia group (r=0.41, p=0.003). Disruption ratings did not correlate with medication 
or symptoms and therefore partial correlations examining the moderating influence of these 
variables on the association with completion rates were not performed.  
3.3 Is validity affected?    
3.3.1 Potential moderators of adherence In the schizophrenia group the overall percentage 
of questionnaires completed did not significantly correlate with chlorpromazine equivalent 
dosage (Spearman’s ρ= -0.04, p=0.75), total PANSS score (r=0.02, p=0.91) or any PANSS 
subscales (r= -0.17-0.22, p=0.14-0.60). There were no significant correlations between Beeps 
1, 2, 4 or 7 (which had significantly reduced completion rates) and medication (Spearman’s 
ρ= -0.08-0.11, p=0.37-0.81), or symptoms (r= -0.23-0.18, p=0.11-0.91). Participants in the 
schizophrenia group who completed fewer than 50% of the beeps at time-point 1 and 2 did 
not significantly differ from the other participants in their levels of medication (F(1,47)=0.21, 
p=0.65), total PANSS score (F(1,47)=0.16, p=0.69) or any PANSS subscales (F(1,47)=0.16-3.73, 
p=0.06-0.69). 
3.3.2 Disruption effects on ESM values The data was bootstrapped to randomly select 5 
beeps a day and to specifically exclude beeps 1 and 2 and the means across the week were 
calculated (see Table 2). The findings suggest that a lower completion rate at certain times 
of day does not alter the conclusions drawn from the data compared to the full dataset or 
randomly selected fewer data points. Although the mean value for positive, not negative, 
affect was significantly reduced at Beeps 1 + 2 compared with the rest of the day in the 
schizophrenia group (t(49)= -2.48, p=0.02).  
---------------------------------------------Table 2 about here------------------------------------------------- 
4. Discussion 
We examined for the first time the external validity of ESM in relation to response rates at 
each beep. This revealed that people with schizophrenia show diurnal variation in their 
completion rates with fewer questionnaires completed in the morning. We know that there 
was no effect of this systematic bias on the ratings made on the ESM device. This is important 
as the adherence to these beeps was also significantly lower in the schizophrenia group 
compared to controls so could have been a source of bias when comparing ESM findings 
between these groups. However, our analysis of mean values excluding these data points 
suggested the impact on validity is minimal in both these groups. As positive affect did show 
a significant reduction in the morning compared to the rest of the day in the schizophrenia 
group, it is still important to sample this time period so as to capture the full range of mood 
experienced.  
As there was no effect of medication dose or symptom levels on completion rates 
there is no evidence that including individuals with chronic schizophrenia and a range of 
symptoms would be detrimental to validity of this type of study. However, this may not be 
the case for other studies which are sampling different outcomes. Our interpretation is that 
the diurnal bias effects we discovered may be due to a disrupted sleep-wake cycle in 
schizophrenia resulting in a later wake-up time (Pedro Afonso et al., 2014).   
Disruption to the week was only considered to be negative in a very small proportion 
of individuals, suggesting minimal responsivity, which is encouraging for future research. 
However, it was associated with reduced questionnaire completion in the schizophrenia 
group which may introduce some bias. The experience of disruption is not related to 
medication, symptoms or particular times of day in this study. These findings suggest that 
medication and symptoms do not therefore act as moderators of the relationship between 
the experience of disruption and completion and therefore do not account for this association 
as may have been hypothesised initially. However, the narrow range of disruption ratings in 
this study limits this conclusion and the influence of medication and symptoms on other 
associations with completion rates e.g. sleep should be investigated in future research. The 
vast majority of ESM studies often fail to record the experience of taking part from the service 
user’s perspective and therefore disruption is often not controlled for in analyses. Not only is 
gathering more information about the service-user experience valuable for experimental 
design but the findings from this study suggest it is important to consider how disrupted the 
individual was during the week when interpreting the results of an ESM study. In particular, 
future studies may wish to ask more directly about responsivity and specifically how much of 
an influence the participant felt the experience of measuring these constructs had on their 
responses.  
It is becoming more common for service-user groups to review experimental protocols 
and questionnaires prior to conducting a study (Reeder et al., 2015). However, there is very 
limited information in the experience sampling literature on the experience feedback and this 
information was not present in the literature. Although this may add to the assessment time 
we feel that the development and optimisation of a method that it is not only patient friendly 
but also patient informed requires this type of feedback to be collected routinely.  
 Future research should build on this work by assessing the acceptability of mobile 
monitoring and interventions in people with a wider range of mental health problems. The 
ability to monitor the symptoms of people in everyday life is important in the prevention of 
relapse, particularly for people with psychosis as relapse is predictive of a worse long term 
prognosis for that individual (Kane, 2013). With this method now being largely implemented 
via mobile phones and the information collected becoming instantly available to clinicians the 
potential to adopt ESM in therapeutic contexts is becoming more apparent and increasingly 
promising.  
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